NEW YORK, May 26, 2017 /PRNewswire/ --
Stock-Callers.com has issued research reports on these four equities: AchillionPharmaceuticals Inc. (NASDAQ: ACHN), Acorda Therapeutics Inc. (NASDAQ: ACOR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Regulus Therapeutics Inc. (NASDAQ: RGLS). According to an article on Investor's Business Daily, the Biotech industry outlook
On Thursday, shares in New Haven, Connecticut headquartered Achillion Pharmaceuticals Inc. rose 0.24%, ending the day at $4.15. The stock recorded a trading volume of 869,489 shares. The Company's shares have advanced 18.57% in the last one month, 7.51% over the previous three months, and 0.48% since the start of this year. The stock is trading above its 50-day moving average by 8.83%. Moreover, shares of Achillion Pharma, which discovers, develops, and commercializes small molecule drug therapies for infectious diseases and immune system disorders in the US and internationally, have a Relative Strength Index (RSI) of 59.54.
On May 04th, 2017, Achillion Pharma reported financial results for the three months ended March 31st, 2017. Net loss for Q1 2017 was $20.2 million; R&D expenses were $15.5 million; general and administrative expenses totaled $5.7 million; and non-cash stock compensation expense totaled $3.2 million. Cash, cash equivalents, marketable securities, and interest receivable as of March 31st, 2017 were $386.6 million.
On May 18th, 2017, research firm Leerink Partners upgraded the Company's stock rating from 'Market Perform' to 'Outperform'. ACHN complete research report is just a click away and free at:
Shares in Ardsley, New York headquartered Acorda Therapeutics Inc. ended the day 3.96% lower at $14.55 with a total trading volume of 638,448 shares. The stock is trading below its 50-day moving average by 22.39%. Shares of the Company, which identifies, develops, and commercializes therapies for neurological disorders in the US, have an RSI of 24.67.
On May 18th, 2017, Acorda Therapeutics announced that it will present new data from the Phase-3 clinical trial of INBRIJA[TM] (levodopa inhalation powder) at the International Congress of Parkinson's Disease and Movement Disorders on June 04th, 2017, through June 08th, 2017, in Vancouver, British Columbia. The Company is developing INBRIJA (CVT-301) as a treatment for symptoms of OFF periods in people with Parkinson's disease taking a carbidopa / levodopa regimen. The complimentary report on ACOR can be downloaded at:
At the close of trading on Thursday, shares in Milton, Canada headquartered Aralez Pharmaceuticals Inc. finished 2.84% lower at $1.37 with a total trading volume of 369,228 shares. The stock is trading below its 50-day moving average by 21.76%. Shares of the Company, which operates as a specialty pharmaceutical company in Canada, Ireland, and the US, have an RSI of 39.33.
On May 23rd, 2017, Aralez Pharma announced that the executive management will participate in the Jefferies Healthcare Conference to be held on June 06th, 2017 through June 09th, 2017, in New York. Adrian Adams, CEO, will provide an overview of the Company at 8:30 a.m. local time on June 07th, 2017. Sign up for your complimentary research report on ARLZ at:
San Diego, California headquartered Regulus Therapeutics Inc.'s shares recorded a trading volume of 2.11 million shares at the end of yesterday's session, which was above their three months average volume of 1.04 million shares. The stock closed the day 3.57% lower at $1.35. The Company's shares have advanced 22.73% in the previous three months. The stock is trading below its 50-day moving average by 9.97%. Additionally, shares of Regulus Therapeutics, which focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the US, have an RSI of 40.88.
On May 04th, 2017, Regulus Therapeutics reported financial results for the three months ended March 31st, 2017. Revenue was less than $0.1 million for the quarter; net loss was $20.0 million; research and development expenses were $15.8 million; and general and administrative expenses were $4.0 million. The Company also reported cash, cash equivalents, and short-term investments of $57.5 million at March 31st, 2017. Get free access to your research report on RGLS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it ...
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...View All